KTT-1
KTT-1 is a kinetically selective and orally active HDAC2 inhibitor. KTT-1 exhibits high HDAC2-selectivity over HDAC1. KTT-1 inhibits osteoclast differentiation at an early stage by downregulating c-Fos expression. KTT-1 effectively suppresses arthritis symptoms in the collagen-induced arthritis (CIA) mouse model. KTT-1 can be used for the research of rheumatoid arthritis and neurodegenerative diseases[1][2].
Product Specifications
CAS Number
2397562-26-2
UNSPSC
12352005
Target
HDAC
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
COVID-19-anti-virus
Field of Research
Inflammation/Immunology; Neurological Disease
Smiles
O=C(NC1=CC(C2=CC=CO2)=CC=C1N)C(C=C3)=CC=C3C(N=N4)=CN4CS(=O)(C5=CC=CC=C5)=O
Molecular Formula
C26H21N5O4S
Molecular Weight
499.54
References & Citations
[1]Yumi Ogihara, et al. The HDAC2-selective inhibitor KTT-1 attenuates autoimmune arthritis by inhibiting osteoclast differentiation in mice. bioRxiv. October 21, 2025.|[2]Mishima H, et al. Origin of the kinetic HDAC2-selectivity of an HDAC inhibitor. J Comput Chem. 2023;44 (18) :1604-1609.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-B404800-50MG 50 mg
4,4'-Bis(4-amino-1-naphthylazo)-2,2'-stilbenedisulfonic Acid (Technical Grade)
Sign In for Pricing
View Details 
BNC880416-500 1x 500 µL
Fascin-1 (FSCN1/416), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNUB2117-500 1x 500 µL
ARF1 (Golgi Apparatus Marker) (ARF1/2117), 0.2mg/mL
Sign In for Pricing
View Details